



# SOLVING URGENT VIRAL DISEASE THREATS

(ASX: ILA)  
2022 Annual General Meeting  
CEO's presentation  
November 2022

# DISCLAIMER

This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Island Pharmaceuticals).

## **Not an offer or financial product advice**

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly any securities, to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities. This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian Corporations Act 2001 (Cth) (**Corporations Act**) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase Securities and does not include any application form for Securities. This presentation does not constitute an advertisement for an offer or proposed offer of Securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

**Financial data** All dollar values are in Australian dollars (\$) or A\$) unless otherwise stated. Any financial data in this presentation is unaudited.  
**Past performance** The operating and historical financial information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of the Company's

views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. You should note that past performance of the Group is not and cannot be relied upon as an indicator of (and provides no guidance as to) future Group performance.

## **Future performance**


This presentation contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "propose", "goals", "targets", "aims", "outlook", "forecasts", "should", "could", "would", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings and financial position and performance are also forward-looking statements. Forward-looking statements in this presentation include statements regarding the Company's future growth options, strategies and new products. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements, including projections, guidance on future operations, earnings and estimates (if any), are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No representation is given that the assumptions upon which forward looking statements may be based are reasonable. This presentation contains statements that are subject to risk factors associated with the Group's industry. These forward-looking statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to earnings, capital expenditure, cash flow and capital structure risks and general business risks.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). In particular, but without limitation, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward looking statements in this presentation will actually occur. Actual operations, results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Any forward looking statements in this presentation speak only as of the date of this presentation.

Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based.

Nothing in this presentation will under any circumstances create an implication that there has been no change in the affairs of the Group since the date of this presentation.



Island Pharmaceuticals (ASX: ILA) is a mid clinical-stage drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases



# ISLAND AT A GLANCE



## Advancing lead drug

ISLA-101 toward Phase 2  
“PEACH” clinical trial for the  
prevention of dengue fever.



## Dengue infects +390 million year

No current pharmaceutical treatment  
for the disease. Limited access to only  
one vaccine.



## Major market potential

In mosquito-borne  
diseases, exacerbated by  
climate change.



## Positive results in aggressive models

Of animal and human cellular models of  
dengue fever and Zika infections + other  
flavivirus data.



## Priority Review Voucher potential

For ISLA-101 at the time of FDA approval.  
Last ten PRVs sold for an average of  
US~\$110M.



## Pipeline expansion underway

Targeting other viruses with  
significant unmet need and  
limited competition.

# THE CHALLENGE



**“DENGUE FEVER IS THE MOST RAPIDLY  
SPREADING MOSQUITO-BORNE VIRUS  
INFECTION IN THE WORLD.”**

World Health Organisation, 13 October 2022



**ISLAND**  
PHARMACEUTICALS  
Antiviral therapeutics

# MOSQUITO BORNE VIRUSES: GLOBAL CHALLENGES



Nov 23, 2021

## Upcoming mosquito season may be the worst yet. Here's how to prepare yourself

Australians are facing a brutal mosquito season bolstered by recent wet weather



## Chikungunya, Zika, and Dengue virus incidence in Mexico may be higher than previously reported

Dec 1, 2021




The researchers found 2.4 times the rate of arbovirosis as originally reported, including coinfections, suggesting underestimation of the incidence of the three viruses. However, future research is needed to provide up-to-date incidence estimates of each virus.



## Singapore is facing a dengue fever 'emergency' and peak season has only just begun

By Annika Burgess and Joshua Boscaini  
Posted 11h ago, updated 10h ago



## Altered by climate change, the U.S. could become ideal for West Nile to thrive



## Here's what we know about the Japanese encephalitis outbreak in Victoria, South Australia, NSW and Queensland

By Freya Michie and Sian Johnson  
Posted Wed 9 Mar 2022 at 1:52pm, updated Wed 9 Mar 2022 at 5:41pm




## In temperate Nepal, climate change paves way for tropical dengue fever

by Abhaya Raj Joshi on 31 October 2022



# WHY DENGUE AS A FIRST TARGET FOR ISLA-101?

SIGNIFICANT UNMET NEED FOR DISEASE WITH INCREASING INCIDENCE



Significant unmet need (3.9 billion people at risk)

Increasing spread to US, EU and Australia

ISLA-101 has both therapeutic and prophylactic potential


Strong animal and human model results

First claim then springboard into other arboviruses

Priority Review Voucher eligibility



# DENGUE IS A WIDESPREAD ISSUE



## HealthMap Reports

Recent reports of local or imported dengue cases from official, newspaper, and other media sources.


Source:

● Country Level ● Local Level

■ Absent ■ Unlikely ■ Uncertain ■ Likely ■ Present

**Dengue outbreaks occurred in many countries of the world in the Americas, Africa, the Middle East, Asia, and the Pacific Islands.**

# DENGUE IN 2050 – A GLOBAL DISEASE



Prediction based on projections of future temperatures, rainfall, and mosquito populations (NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford.)

# LIMITED AVAILABLE SOLUTIONS

## HIGHLY PREVALENT DISEASES WITH UNMET MEDICAL NEED



**Worldwide prevalence**

Dengue fever	West Nile	Zika Virus	Yellow fever	Japanese Encephalitis
--------------	-----------	------------	--------------	-----------------------

390 million	n/a	Up to 1.5 million	130,000	70,000
-------------	-----	-------------------	---------	--------



Viral diseases are a leading cause of endemic and pandemic disease



**Effective drug therapy**

No	No	No	No	No
----	----	----	----	----



Antimalarial drugs market is expected to reach US\$1B in 2026 providing guidance to potential market size



**Vaccine**

Limited	No	No	Limited	Limited
---------	----	----	---------	---------



Vaccine development potentially can exacerbate symptoms from infections by different strains

# ISLA-101



**ISLAND**  
PHARMACEUTICALS  
Antiviral therapeutics

# ISLA-101 REPURPOSED DRUG

DRAMATICALLY REDUCES DEVELOPMENT TIME, RISK AND COST



**ISLA-101, originally a cancer drug**



**Demonstrated as safe in humans**



**Strong regulatory history and acceptance**



**Speed to market & early revenue potential**



**Capitalising on millions spent**



Originally identified by Johnson & Johnson and studied as a potential chemotherapy

Used in 45 clinical studies (including Phase II & III) demonstrating an excellent safety profile in thousands of patients including children


Multiple regulatory jurisdictions have reviewed ISLA-101 as having a well established safety profile

Clearance of early phases allows many years to be saved in drug development and quick path to market

Funds and time spent to date reduce risk and allow for immediate move to Phase II study

# ISLA-101 BROAD ACTIVITY EVIDENT


DEMONSTRATED ACTIVITY AGAINST FLAVIVIRUSES (A SUBGROUP OF ARBOVIRUSES) IN MULTIPLE MODELS OF INFECTION



- In *in-vitro* models using fresh human cells, ISLA-101 has demonstrated broad anti-viral activity
- In animal models, ISLA-101 is protective in dengue fever and Zika
- In extremely lethal animal models, ISLA-101 was shown to prevent death in 70% of subjects
- Increasing concentrations of ISLA-101 prevent death induced by an otherwise lethal dengue fever infection
- 45 HUMAN Clinical Studies of ISLA-101 completed in other indications

# PATHWAY / TIMING TO CLINICAL TRIALS

MULTIPLE WORKSTREAMS WILL TAKE US TO FDA REVIEW OF OUR IND



# MANUFACTURING PROGRESS



**Manufactured capsules being processed**



**Packaged bottles awaiting stability results**



# PHASE II DENGUE (PEACH) TRIAL STUDY IN DETAIL



Antiviral therapeutics

“PEACH” STUDY- A PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY FOR THE PROPHYLACTIC EXAMINATION OF AN ANTIVIRAL IN A DENGUE CHALLENGE MODEL

## Phase II trial protocol

Up to 4 cohorts/4 arms

### Inclusion

- Healthy subjects
- Age 18-55
- Willing to use contraception for the duration of the study
- Informed consent

### Exclusion


- Female: pregnant or lactating
- Prior infection with HIV, HCV, Flaviviruses
- Current, or a history of, auto-immune disease

### Primary endpoint

- Assess the prophylactic effect of ISLA 101 on fever, clinical symptoms, laboratory abnormalities and viremia after challenge with DENV-1-LVHC

### Secondary endpoints

- Characterise the clinical, immunologic and virologic responses following ISLA 101 after challenge with DENV-1-LVHC
- Assess the safety of ISLA 101 in the challenge with DENV-1-LVHC



The study will be run at SUNY Upstate Medical University Syracuse, New York

# THE COMMERCIAL OPPORTUNITY



# COMMERCIAL OPPORTUNITY



Prophylactic for  
travelers



Military



National  
outbreaks



Government  
Stockpiles



Priority Review  
Voucher



## Tropical area travellers opportunity:

- Comparable to malaria market - expected to reach US\$1B in 2026\*
- Increasing numbers of countries due to global warming

## Military opportunity:

- Isla is partnering with army (CRADA in place) for Phase 2a clinical trial in Dengue Fever
- We will pursue a contract with the military as we get closer to approval

## Endemic area opportunity:

- Many millions of patients in Central and South America
- Potential for sales for disease suppression and treatment during outbreaks
- Potential for endemic countries to establish and maintain drug stockpiles as happens with influenza

# TIMELINE NOW FALLING INTO PLACE

**H1 FY 2022**  
(July-Dec 2021)

- ✓ Sign SUNY CTA
- ✓ Announce Principal Investigator
- ✓ Engaged CRO
- ✓ Drug substance (API) manufactured
- ✓ Advance research collaboration

**H2 FY 2022**  
(Jan-June 2022)

- ✓ New drug product manufacturer secured
- ✓ Analytical method development
- ✓ Advancing IND

**H1 FY 2023**  
(July-Dec 2022)

- ✓ Clinical material manufactured
- Clinical material released and shipped to site
- Finalize and File IND
- File IRB

**H2 FY 2023**  
(Jan-June 2023)

- Open IND
- Screening, enrolment, dosing subjects in PEACH\* trial
- Advance through PEACH cohorts
- Trial read out
- Identify lead molecules from research collaborations

\* PEACH: Phase 2a, randomized, double blind, placebo-controlled study for the Prophylactic Examination of an Antiviral in a Dengue Challenge Model.

# BOARD, MANAGEMENT & SCIENTIFIC BOARD

## BOARD & MANAGEMENT TEAM



**Dr. Paul MacLeman**  
Executive Chair



**Dr. David Foster**  
CEO & Executive Director



**Dr. Anna Lavelle**  
Non-Executive Director



**Mr. Al Hansen**  
Non-Executive Director



**Dr. David Brookes**  
Non-Executive Director

## SCIENTIFIC ADVISORY BOARD



**Teresa Byrne**  
Vice President Clinical  
Product Development



**Kevin Swiss, CMC**  
Consultant



**Assoc. Prof. Leigh Farrell**



**Prof. Stephen Thomas MD**



**Dr. Amy Patick**



**ISLAND**  
PHARMACEUTICALS  
Antiviral therapeutics

David Foster  
Chief Executive Officer & Executive Director  
[dfoster@islandpharmaceuticals.com](mailto:dfoster@islandpharmaceuticals.com)

Authorized for release by Paul MacLeman, Executive Chairman

[www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com)  
Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia

Island Pharmaceuticals  
Limited

ACN 641 183 842